PRINCETON, N.J., Feb. 2 /PRNewswire-FirstCall/ -- China Biopharma, Inc. announced today that it has reached an agreement of understanding with a biopharmaceutical firm in China to expand its product line from human vaccines to intravenous therapies for the treatment of autoimmune diseases. China Biopharma plans to market Intravenous Immunoglobulin (IVIG) on the international market beginning in the second quarter of 2007. IVIG is a solution containing blood components, specifically immunoglobulins that help regulate the immune system. IVIG is used to treat a host of life-threatening and serious autoimmune diseases, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a form of nerve disease or peripheral neuropathy. IVIG and its components represent a multi-billion dollar market.
Peter Wang, CEO of China Biopharma, Inc., states, “We will continue to develop and distribute vaccines in China, while we diversify our product line into biological treatments that target several of today’s most prevalent diseases. IVIG has emerged as an important therapy for various neurological diseases and is also a life-saving treatment for patients with autoimmune diseases. Due to its limited supply outside the U.S., availability of IVIG is still inadequate in a number of countries. As a result, the price for IVIG has increased dramatically in the last few years, creating a very promising new market opportunity for China Biopharma.”
About China Biopharma Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the Company develops and distributes human vaccine products throughout the world’s most populated country, China. Products include human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international vaccine providers, China Biopharma is building a highly-competitive platform for growth in China as well as new markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.com.cn.
Safe Harbor Statement
Some of the statements made in this press release discuss future events and developments, including the Company’s future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements can generally be identified by words such as “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan,” and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company’s operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company’s new and uncertain
business model, uncertainty regarding acceptance of the Company’s products and services and the Company’s limited operating history.
CONTACT: At the Company: George Ji China Biopharma, Inc. Tel: +1 (609) 651-8588 ir@chinabiopharma.nethttp://www.chinabiopharma.com.cn Investor Relations: OTC Financial Network Peter Clark Tel: +1 (781) 444-6100x629 peter@otcfn.com
China Biopharma, Inc.
CONTACT: George Ji of China Biopharma, Inc., +1-609-651-8588,ir@chinabiopharma.net; or Investor Relations: Peter Clark of OTC FinancialNetwork, +1-781-444-6100x629, peter@otcfn.com
Web site: http://www.chinabiopharma.com.cn//
